Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Disodium folinate 100mg/2ml solution for injection vials
0801000X0AAAAAA
|
Disodium folinate | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Disodium folinate 200mg/4ml solution for injection vials
0801000X0AAADAD
|
Disodium folinate | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Disodium folinate 400mg/8ml solution for injection vials
0801000X0AAABAB
|
Disodium folinate | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Disodium folinate 50mg/1ml solution for injection vials
0801000X0AAAEAE
|
Disodium folinate | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Disodium folinate 900mg/18ml solution for injection vials
0801000X0AAACAC
|
Disodium folinate | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Sodiofolin 100mg/2ml solution for injection vials
0801000X0BBAAAA
|
Sodiofolin | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Sodiofolin 400mg/8ml solution for injection vials
0801000X0BBABAB
|
Sodiofolin | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
|
Sodiofolin 900mg/18ml solution for injection vials
0801000X0BBACAC
|
Sodiofolin | Disodium folinate | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.